AstraZeneca Pharma Stock May Extend Rally As Momentum Strengthens: SEBI RA Finversify
Synopsis
According to Finversify, the company may extend its rally after crossing the ₹9,200 swing high, which also identified ₹7,810 as key support.
AstraZeneca Pharma India Ltd. could maintain its upward trajectory after surpassing its former swing high of ₹9,200, according to SEBI-registered research firm Finversify.
At the time of writing, AstraZeneca Pharma India shares were trading at ₹8,879.00, up 11.4% on the day.
Finversify said the Average Directional Index (ADX) shows positive momentum, which signals growing trend strength.
The research firm established ₹7,810 as a key support level.
Stock prices rose by 8% following the company's announcement of a 47.7% annual increase in fourth-quarter (Q4) net profit, reaching ₹58.2 crore.
The pharma company also posted a 25.4% revenue growth to ₹480.4 crore.
Meanwhile, core profit increased by 75% to ₹86 crore, while profit margins climbed 500 basis points, reaching 17.96%.
The stock has risen nearly 30% during the previous six months and is headed for a third straight session of gains.
On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.
The stock has risen 23.4% so far in 2025.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.